Boryung Pharmaceutical Co., Ltd: Essential Hypertension trials

The registry lists 46 Essential Hypertension studies with Boryung Pharmaceutical Co., Ltd as lead sponsor. 8 are open to participants now and 3 have results posted.

Phase 1 23Phase 2 5Phase 3 13No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.Not yet recruitingNCT07685054
• A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed ConditionsNot yet recruitingNCT07421414Phase 1
• A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting ConditionsNot yet recruitingNCT07421401Phase 1
• A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed ConditionsNot yet recruitingNCT07421388Phase 1
• A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting ConditionsNot yet recruitingNCT07421375Phase 1
• A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential HypertensionNot yet recruitingNCT07373613Phase 2
• A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination TherapyRecruitingNCT06220773Phase 3
• An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZRecruitingNCT05413057
• FimasaRtan-basEd BP Targets After Drug SwitcHingCompletedNCT03649646Results posted
• Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan)CompletedNCT02385721Results posted
• A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential HypertensionCompletedNCT00922441Phase 2Results posted
• A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult VolunteersCompletedNCT06889064Phase 1
• A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult VolunteersCompletedNCT06889012Phase 1
• A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed ConditionsCompletedNCT06744439Phase 1
• A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting ConditionsCompletedNCT06744426Phase 1
• A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting ConditionsCompletedNCT06744127Phase 1
• A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed ConditionsCompletedNCT06744062Phase 1
• A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy VolunteersCompletedNCT06636877Phase 1
• A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"CompletedNCT06226727Phase 1
• A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"CompletedNCT06184269Phase 1
• A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018CCompletedNCT06165250Phase 3
• A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary HypercholesterolemiaCompletedNCT05930028Phase 3
• A Study to Evaluate the Efficacy and Safety of BR1015 Combination TherapyCompletedNCT05878561Phase 3
• An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and ProteinuriaCompletedNCT05086549
• BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine CombinationCompletedNCT03991442Phase 3
• A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and DyslipidemiaCompletedNCT03338426Phase 3
• Fimasartan in the Senior SubjectsCompletedNCT03246555Phase 3
• Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and DyslipidemiaCompletedNCT03156842Phase 3
• A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and DyslipidemiaCompletedNCT02166814Phase 3
• Fimasartan/Amlodipine Combination Phase IIICompletedNCT02152306Phase 3
• A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential HypertensionCompletedNCT01878201Phase 2
• A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential HypertensionCompletedNCT01672476Phase 3
• Fimasartan (BR-A-657) Multiple Oral Dose in Healthy SubjectsCompletedNCT01289899Phase 1
• Fimasartan (BR-A-657) Single Oral Dose in Healthy SubjectsCompletedNCT01289886Phase 1
• A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapyCompletedNCT01258673Phase 3
• A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy VolunteersCompletedNCT01146938Phase 1
• The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential HypertensionCompletedNCT01135212Phase 3
• A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male VolunteersCompletedNCT00991783Phase 1
• A Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male VolunteersCompletedNCT00991705Phase 1
• A Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male VolunteersCompletedNCT00938262Phase 1
• A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male VolunteersCompletedNCT00938197Phase 1
• A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male VolunteersCompletedNCT00938132Phase 1
• Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)CompletedNCT00937651Phase 2
• Study to Compare and Assess the Safety and Pharmacokinetic Characteristics After Oral Administration of Fimasartan (BR-A-657∙K) in Healthy Elderly and Young Male VolunteersCompletedNCT00937534Phase 1
• Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension PatientsCompletedNCT00923611Phase 2
• A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male VolunteersCompletedNCT00923533Phase 1